Real-world comparative effectiveness, safety, and health care costs of oral anticoagulants in nonvalvular atrial fibrillation patients in the US Department of Defense …
BACKGROUND: The ARISTOTLE trial demonstrated that apixaban had significantly lower
rates of stroke/systemic embolism (SE) and major bleeding than warfarin; however, no direct …
rates of stroke/systemic embolism (SE) and major bleeding than warfarin; however, no direct …
Real-world effectiveness and safety of oral anticoagulation strategies in atrial fibrillation: a cohort study based on a German claims dataset
S Mueller, A Groth, SG Spitzer, A Schramm… - Pragmatic and …, 2018 - Taylor & Francis
Objective To compare the real-world effectiveness and safety of non-vitamin-K-antagonist
oral anticoagulant (NOAC) treatment in atrial fibrillation (AF) patients with a vitamin-K …
oral anticoagulant (NOAC) treatment in atrial fibrillation (AF) patients with a vitamin-K …
[HTML][HTML] A review of global health technology assessments of non-VKA oral anticoagulants in non-valvular atrial fibrillation
RD Lopes, SE Berger, M Di Fusco, A Kang… - International Journal of …, 2020 - Elsevier
Background This review assessed global health technology assessment (HTA) reports and
recommendations of non-vitamin K oral anticoagulants (NOACs) in non-valvular atrial …
recommendations of non-vitamin K oral anticoagulants (NOACs) in non-valvular atrial …
[HTML][HTML] Patients' priorities for oral anticoagulation therapy in non-valvular atrial fibrillation: a multi-criteria decision analysis
MGM Weernink, MCW Vaanholt… - American Journal of …, 2018 - Springer
Introduction Effectiveness of oral anticoagulants (OACs) is critically dependent on patients'
adherence to intake regimens. We studied the relative impact of attributes related to …
adherence to intake regimens. We studied the relative impact of attributes related to …
Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation—a cost-effectiveness analysis
JHS You - Journal of general internal medicine, 2014 - Springer
ABSTRACT BACKGROUND The decision as to whether to use more expensive novel oral
anticoagulants (NOACs) or invest resources for quality improvement of warfarin therapy …
anticoagulants (NOACs) or invest resources for quality improvement of warfarin therapy …
A real-world observational study of hospitalization and health care costs among nonvalvular atrial fibrillation patients prescribed oral anticoagulants in the US …
A Amin, A Keshishian, J Trocio, O Dina, H Le… - Journal of Managed …, 2018 - jmcp.org
This article has been corrected. Please see J Manag Care Spec Pharm, 2020; 26 (5): 682
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
[HTML][HTML] Safety, effectiveness, and cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in …
Approximately 250,000 Canadians are affected by atrial fibrillation (AF). Stroke is a
complication of AF, and Canadians with AF are five times more likely to have a stroke and …
complication of AF, and Canadians with AF are five times more likely to have a stroke and …
Cost-effectiveness of novel oral anticoagulants for stroke prevention in non-valvular atrial fibrillation
SM Singh, HC Wijeysundera - Current cardiology reports, 2015 - Springer
Recently, novel oral anticoagulants (NOACs) have been approved for stroke prevention in
patients with atrial fibrillation (AF). Although these agents overcome some disadvantages of …
patients with atrial fibrillation (AF). Although these agents overcome some disadvantages of …
A real-world observational study of hospitalization and health care costs among nonvalvular atrial fibrillation patients prescribed oral anticoagulants in the US …
A Amin, A Keshishian, J Trocio, O Dina, H Le… - Journal of Managed …, 2020 - jmcp.org
This article has been corrected. Please see J Manag Care Spec Pharm, 2020; 26 (5): 682
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
[HTML][HTML] Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina
MA Giorgi, C Caroli, ND Giglio, P Micone… - Health Economics …, 2015 - Springer
Apixaban, a novel oral anticoagulant which has been approved for the prevention of stroke
and systemic embolism in non-valvular atrial fibrillation, reduces both ischemic and …
and systemic embolism in non-valvular atrial fibrillation, reduces both ischemic and …